A role for natural killer cells in the rapid death of cultured donor myoblasts after transplantation
- 1 March 2003
- journal article
- immunobiology
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (6) , 863-871
- https://doi.org/10.1097/01.tp.0000053754.33317.4b
Abstract
Background. The rapid and massive death of cultured donor myoblasts after injection in vivo is a major problem for clinical myoblast transfer therapy (MTT). This study shows blood-borne factors are responsible and that ablating the host natural killer (NK) cell response greatly enhances the survival of such donor myoblasts. Methods. Cultured male donor myoblasts were injected into muscles of female host mice and surviving donor male DNA (myoblasts) quantified using a Y-chromosome specific (Y1) probe. Survival of donor myoblasts transfected with m144, a murine major histocompatibility complex (MHC) class I homologue that protects against NK attack, was quantified. In addition, donor myoblast survival was investigated in host mice following initial (before MTT) and sustained (repeatedly for 3 weeks after MTT) depletion of host NK1.1+ and CD4+/CD8+ cells using specific monoclonal antibodies (either alone or in combination) for up to 3 weeks after MTT, as well as in beige (deficient in NK activity) and in perforin-deficient mdx host mice. Results. A major role for blood-borne factors (especially cells) was confirmed by MTT experiments in irradiated and perfused host mice. Substantially enhanced myoblast survival was seen with donor myoblasts modified by transfection with the m144 molecule or following antibody depletion of host NK1.1+ cells and in beige host mice. Other studies support some role for CD8+ but not CD4+ cells. Conclusions. These combined data support a central role for host NK cells in the rapid initial death of donor myoblasts. The demonstrated role of NK cells provides strategies to enhance the efficacy of clinical myoblast transplantation.Keywords
This publication has 25 references indexed in Scilit:
- Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28−/− miceNature Medicine, 2001
- Problems and solutions in myoblast transfer therapyJournal of Cellular and Molecular Medicine, 2001
- Why Do Cultured Transplanted Myoblasts Die in Vivo? DNA Quantification Shows Enhanced Survival of Donor Male Myoblasts in Host Mice Depleted of CD4+ and CD8+ Cells or NK1.1+ CellsCell Transplantation, 2000
- The human natural killer cell immune synapseProceedings of the National Academy of Sciences, 1999
- NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate CytokinesAnnual Review of Immunology, 1999
- Dynamics of Myoblast Transplantation Reveal a Discrete Minority of Precursors with Stem Cell–like Properties as the Myogenic SourceThe Journal of cell biology, 1999
- XENOGENEIC TRANSPLANTATIONAnnual Review of Immunology, 1998
- A DUAL-MARKER SYSTEM FOR QUANTITATIVE STUDIES OF MYOBLAST TRANSPLANTATION IN THE MOUSE1Transplantation, 1997
- A Potential Alternative Strategy for Myoblast Transfer Therapy: The use of Sliced Muscle GraftsCell Transplantation, 1996
- Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation.Journal of Clinical Investigation, 1990